4.7 Article

PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis

期刊

CELL DEATH & DISEASE
卷 12, 期 11, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41419-021-04381-5

关键词

-

资金

  1. National Natural Science Foundation of China [82173060, 82072649, 81872304]
  2. Outstanding Youth Foundation of Jiangsu Province, China [BK20200046]
  3. Natural Science Foundation of Jiangsu Province, China [BK20180989, BK20170261]
  4. National Postdoctoral Research Funds of China [2019M651971, 2021T140577]
  5. Xuzhou City Science and Technology Plan Project of Jiangsu Province, China [KC19065]

向作者/读者索取更多资源

This study uncovers the critical role of PRMT1-mediated methylation of EZH2 at the R342 site in promoting breast cancer cell proliferation, accelerating cell cycle progression, repressing P16 and P21 transcription, and enhancing EZH2 binding with SUZ12 and PRC2 assembly. Additionally, it highlights the potential of meR342-EZH2 as a novel therapeutic target for breast cancer treatment, indicating a negative correlation with pT311-EZH2 expression.
Protein arginine methyltransferase 1 (PRMT1) is able to promote breast cancer cell proliferation. However, the detailed mechanisms of PRMT1-mediated breast cancer cell proliferation are largely unknown. In this study, we reveal that PRMT1-mediated methylation of EZH2 at the R342 site (meR342-EZH2) has a great effect on PRMT1-induced cell proliferation. We also demonstrate that meR342-EZH2 can accelerate breast cancer cell proliferation in vitro and in vivo. Further, we show that meR342-EZH2 promotes cell cycle progression by repressing P16 and P21 transcription expression. In terms of mechanism, we illustrate that meR342-EZH2 facilitates EZH2 binding with SUZ12 and PRC2 assembly by preventing AMPK alpha 1-mediated phosphorylation of pT311-EZH2, which results in suppression of P16 and P21 transcription by enhancing EZH2 expression and H3K27me3 enrichment at P16 and P21 promoters. Finally, we validate that the expression of PRMT1 and meR342-EZH2 is negatively correlated with pT311-EZH2 expression. Our findings suggest that meR342-EZH2 may become a novel therapeutic target for the treatment of breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据